(See WARNINGS regarding induction of neoplasia, adverse effects on the fetus, increased incidence of gall bladder disease, and adverse effects similar to those of oral contraceptives, including thromboembolism.) The following additional adverse reactions have been reported with estrogenic therapy, including oral contraceptives:
1. Genitourinary system.
- Increase in size of uterine fibromyomata.
- Vaginal candidiasis.
- Breakthrough bleeding, spotting, change in menstrual flow.
- Dysmenorrhea. Premenstrual-like syndrome.
- Amenorrhea during and after treatment.
- Change in cervical eversion and in degree of cervical secretion.
- Cystitis-like syndrome.
Tenderness, enlargement, secretion.
- Cholestatic jaundice.
- Nausea, vomiting.
- Abdominal cramps, bloating.
- Erythema multiforme.
- Erythema nodosum.
- Hemorrhagic eruption.
- Loss of scalp hair.
- Chloasma or melasma which may persist when drug is discontinued.
- Steepening of corneal curvature.
- Intolerance to contact lenses.
- Mental depression.
- Headache, migraine, dizziness.
- Reduced carbohydrate tolerance.
- Aggravation of porphyria.
- Changes in libido.
- Increase or decrease in weight.